한빛사 논문
ll-Young Jang1,2, Eunju Lee1, Heayon Lee1, Hyungchul Park1, Sunyoung Kim3, Kwang-il Kim4, Hee-Won Jung5,* & Dae Hyun Kim6,7
1 Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, 2 PyeongChang Health Center and County Hospital, PyeongChang, Gangwon-Do, Republic of Korea, 3 Department of Family Medicine, Kyung Hee University Medical Center, Seoul, Republic of Korea, 4 Division of Geriatrics, Department of Internal Medicine, Seoul National University Bundang Hospital, Republic of Korea, 5 Department of Internal Medicine, Seoul National University Hospital,Seoul, Republic of Korea, 6 Marcus Institute for Aging Research, Hebrew Senior Life, Boston, MA, USA, 7 Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA
*Correspondence to: Hee-Won Jung, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Abstract
Background
We aimed to assess the clinical characteristics of sarcopenia by the original and revised European Working Group on Sarcopenia in Older People (EWGSOP 1 and 2), and to propose a new sarcopenia phenotype score (SPS) to improve relevance of clinical outcomes.
Methods
Analyses were performed in 1408 older adults of the Aging Study of PyeongChang Rural Area, a community‐based cohort in Korea. For sarcopenia definitions, we used EWGSOP 1, EWGSOP 2, and SPS, a new index counting number of abnormal domains among components of grip strength, gait speed, or muscle mass. Frailty status by the frailty index and the Cardiovascular Health Study frailty score was compared with sarcopenia measures. Prediction ability for composite outcome combining death and institutionalization due to functional decline was assessed among sarcopenia measures.
Results
Generally, sarcopenia spectrum by both EWGSOP 1 and 2 was associated with worse functional status in parameters of geriatric assessments. However, population who were considered as sarcopenic by EWGSOP 1, but not by EWGSOP 2, showed increased risk of composite outcome and worse frailty status, compared with people who were classified as not sarcopenic by both EWGSOP 1 and 2. With SPS, dose–response relationship was observed with both frailty status and outcome prediction. Prediction for composite outcome was better in SPS than in EWGSOP 2 classification.
Conclusions
A new SPS might be used to classify sarcopenic burden in older adults to resolve possible inconsistencies in phenotype correlation and outcome prediction of EWGSOP 2 criteria
Keywords : Sarcopenia, Frailty, Validationm, Outcome, Prospective study
논문정보
관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기